(Q45072359)

English

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

scientific article published in October 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

9 December 2017

1 reference

based on heuristic

inferred from title

0 references

author name string

Alan N Gordon

1

1 reference

Europe PubMed Central

9 December 2017

Margaret Tonda

2

1 reference

Europe PubMed Central

9 December 2017

Steven Sun

3

1 reference

Europe PubMed Central

9 December 2017

Wayne Rackoff

4

1 reference

Europe PubMed Central

9 December 2017

Doxil Study 30-49 Investigators

5

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

9 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

9 December 2017

95

1 reference

Europe PubMed Central

9 December 2017

1-8

1 reference

Europe PubMed Central

9 December 2017

1

1 reference

Europe PubMed Central

9 December 2017

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Chemotherapy for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.011

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.07.011

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45072359&oldid=2064552794"